4//SEC Filing
Eaton Bruce 4
Accession 0001415889-23-004312
CIK 0001650664other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:30 PM ET
Size
9.1 KB
Accession
0001415889-23-004312
Insider Transaction Report
Form 4
Eaton Bruce
EVP, Chief Business Officer
Transactions
- Award
Common Stock
2023-03-02+16,700→ 77,683 total - Sale
Common Stock
2023-03-03$8.89/sh−101$898→ 77,582 total - Award
Stock Option (right to buy)
2023-03-02+50,000→ 50,000 totalExercise: $8.72Exp: 2033-03-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
- [F2]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
- [F3]This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.
Documents
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001874831
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:30 PM ET
- Size
- 9.1 KB